Exenatide

Combination dapagliflozin/exenatide acutely raised β-cell function index fourfold vs placebo (1.69 vs 0.40), exceeding exenatide (threefold) and dapagliflozin (62% higher).; Corrected Matsuda index (insulin sensitivity) was higher with all active treatments vs placebo acutely, and increased further at 1 and 4 months with dapagliflozin and combination therapy.; Insulin secretion was higher with exenatide and combination vs dapagliflozin or placebo acutely and remained higher through 4 months.; β-cell function continued to rise over 4 months with dapagliflozin and exenatide monotherapy but did not increase further after the acute phase with combination therapy.

Exenatide group lost 0.5 kg (-0.6%) while placebo group gained 2.6 kg (+2.8%) (both p < .01).; Common side effects with exenatide were gastrointestinal symptoms and headaches.; No clinically meaningful changes in mood or psychotic symptoms between groups.; Exenatide was effective and well-tolerated for attenuating olanzapine-associated weight gain.

Exenatide was more effective than placebo in participants smoking >20 cigarettes per day (PP = 81.7%).; Greater exenatide benefit was observed in participants without prediabetes (PP = 76.0%) and without obesity (PP = 94.4%).; Exenatide efficacy was limited to individuals with no/minimal depression symptoms (PP = 91.2%).; Exenatide was more efficacious only in those with the CHRNA rs16969968 GG genotype (PP = 88.6%).

No significant difference in remission duration between exenatide-ER (662 days) and placebo (669 days), p=0.9.; Exenatide-ER maintained hemoglobin A1c (-0.05%) whereas placebo increased (+2.3%), p=0.03.; Both groups experienced modest weight loss at study exit (placebo -0.6 kg, exenatide-ER -0.2 kg).; Three cats relapsed (1 placebo, 2 exenatide-ER), with 13 completing the 2-year study without relapse.

Exenatide administration at ZT 12 counteracted the phase shift effect of light-period time-restricted feeding on the hepatic clock in wild-type mice, whereas dosing at ZT 0 enhanced it.; Exenatide did not influence the phase of the hepatic clock under dark-period time-restricted feeding regardless of dosing time.; The effect of exenatide in wild-type mice weakened in central nervous system-specific GLP-1 receptor knockdown mice.; Exenatide dosing at the beginning of the active period might prevent disruption of peripheral clocks caused by irregular eating habits.

First study to discuss anaphylactic shock from exenatide reexposure in a patient who had interrupted exenatide treatment; Patient presented with localized urticaria, lip pallor, hand tremors, nausea, vomiting, chest stuffiness, dizziness, confusion, and dyspnea, with blood glucose 4.6 mmol/L and blood pressure 85/50 mm Hg; Exenatide, though not prone to anaphylaxis, is a synthetic peptide with immunogenicity that can induce antibody formation and elicit allergic reactions; Clinicians should pay close attention to the potential for anaphylactic shock when prescribing exenatide for diabetics

What is Exenatide?

**Mechanism of Action** Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster (*Heloderma suspectum*). It acts as a potent and selective agonist of the glucagon-like peptide-1 (GLP-1) receptor, a class B G-protein-coupled receptor. By mimicking endogenous incret

How does Exenatide work?

Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.

What is the research status of Exenatide?

Exenatide is currently classified as approved, with 2,877 research references on record. This is for research purposes only and is not medical advice.

What is the half-life of Exenatide?

The reported half-life of Exenatide is ~2.4 hours.

What is the molecular weight of Exenatide?

Exenatide has a molecular weight of approximately 4187 g/mol (formula C184H282N50O60S).